ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2048

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 1833

Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

(1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 1845

Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 2022

Development of an mHealth App for Lupus: Insights from a Human-Centered Design Approach

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2018

Development of an Osteoporosis Treatment Gap Dashboard

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2184

Development of Salivary Gland Organoids to Study Sjögren Syndrome

(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1910

Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2101

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2197

Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2396

Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 1877

Diagnostic Yield of 18F-FDG PET-CT for Large Vessel Involvement in Patients with Suspected Giant Cell Arteritis and Negative Temporal Artery Biopsy

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: L05

DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis

Late-Breaking Abstract Poster

9:00AM-11:00AM: Abstract Number: 2224

Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2251

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 2266

Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].